<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83512">
  <stage>Registered</stage>
  <submitdate>15/01/2009</submitdate>
  <approvaldate>18/02/2009</approvaldate>
  <actrnumber>ACTRN12609000111279</actrnumber>
  <trial_identification>
    <studytitle>The effects of memantine versus placebo on visual functions after scleral buckling for regmatogenous retinal detachment (RRD)</studytitle>
    <scientifictitle>The effects of memantine versus placebo on visual acuity , optical coherence tomogapy (OCT) , contrast sensitivity , multifocal electroretinography (mERG) after scleral buckling for regmatogenous retinal detachment  (RRD)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>patients with rhegmatogenus retinal detachment undergoing scleral buckeling surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>intervention: Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks)</interventions>
    <comparator>Placebo (550 miligram of lactose powder) for control group, daily for three weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Any change in visual acuity, testing by Early Treatment Diabetic Retinopathy Study (ETDRS) chart in LogMAR (Logarithmic value for Minimum Angle of Resolution)</outcome>
      <timepoint>Baseline, then on months 1, months 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Any change in central macular thickness measured by optical coherence tomography (OCT)</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amplitudes of P waves in central macula measured by performing multifocal electroretinography (mERG) developed by Metrovision</outcome>
      <timepoint>3 months after operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Contast sensitivity measurement in 4.8, 7.5, 12, &amp; 15 cycle per degree measured by B-VATII Mentor</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Macula off  rhegmatogenus retinal detachment (RRD)
Duration&lt;4 weeks
Proliferative vitreoretinopathy (PVR) A ;B
Visual acuity (V/A) &lt; 20/200</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Usage of digoxin and dextrometorphan (interacting with memantine)
Pregnancy an nursing
Renal disease
Failure of surgery
Longstanding retinal detachment (RD)
Other macular pathology</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed envelopes</concealment>
    <sequence>Stratified allocation depending on 1:duration of RD (&lt;2 weeks and &gt;2 weeks) and 2: patient lens status(phakic versus pseudophakic or aphakic) randomised by permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects, therapist or clinician, assessor, and data analyst were all masked</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>20/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of Medical sciences</primarysponsorname>
    <primarysponsoraddress>Tehran university, Enghelab Square, Tehran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Ophthalmology department/ school of medicine/ Medical Sciences/ Tehran University</fundingname>
      <fundingaddress>Farabi Eye Hospital, Qazvin Square, Tehran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluation of the neuroprotective effect of Memantine in visual function of patients with macula off RRD of less than 1 months duration. Our hypothesis was that Memantine helps for better improvement of visual function in these patientsafter successful scleral buckling.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The investigational review board and ethics committees of Tehran University of Medical Sciences</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Qazvin Square, Tehran</address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Qazvin Square, Tehran</address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Qazvin Square, Tehran</address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>